Compare PRPO & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | PIII |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Nursing Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 33.8M |
| IPO Year | 2000 | 2021 |
| Metric | PRPO | PIII |
|---|---|---|
| Price | $29.44 | $8.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 97.5K | 31.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $24,049,000.00 | ★ $1,459,080,000.00 |
| Revenue This Year | N/A | $7.67 |
| Revenue Next Year | N/A | $2.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.77 | N/A |
| 52 Week Low | $14.28 | $1.52 |
| 52 Week High | $33.63 | $16.89 |
| Indicator | PRPO | PIII |
|---|---|---|
| Relative Strength Index (RSI) | 65.82 | 39.35 |
| Support Level | $21.45 | $2.17 |
| Resistance Level | $33.63 | $11.55 |
| Average True Range (ATR) | 2.14 | 0.78 |
| MACD | 0.53 | -0.17 |
| Stochastic Oscillator | 73.67 | 0.80 |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.